Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

Gut

Volumn 53, Issue 3, 2004, Pages 413-419

  Hickman, I J ^b   Jonsson, J R ^b   Prins, J B ^a   Ash, S ^a   Purdie, D M ^c   Clouston, A D ^b   Powell, E E ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; INSULIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; BODY WEIGHT; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; EXERCISE; FEMALE; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; MALE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; STATISTICAL SIGNIFICANCE; WEIGHT REDUCTION;

ADULT; ALANINE TRANSAMINASE; ANTHROPOMETRY; CHRONIC DISEASE; D-ALANINE TRANSAMINASE; EXERCISE; FASTING; FATTY LIVER; FEMALE; HUMANS; INSULIN; LIFE STYLE; MALE; MIDDLE AGED; OBESITY; PATIENT COMPLIANCE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; WEIGHT LOSS;

EID: 1242340436     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.027581     Document Type: Article

References (31)

1. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9.
2. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
3. McCullough A. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002;34:255-62.
4. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
5. Nakao K, Nakata K, Ohtsubo N, et al. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol 2002;97:1796-801.
6. Clouston AD, Powell EE. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol 2002;16:767-81.
7. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
8. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-19.
9. Hickman IJ, Powell EE, Prins JB, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003;39:1042-8.
10. Raynard B, Balian A, Fallik D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002;35:635-8.
11. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94.
12. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999;29:264-70.
13. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-12.
14. Ware JE jr, Bayliss MS, Mannocchia M, et al. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999;30:550-5.
15. Hussain KB, Fontana RJ, Moyer CA, et al. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol 2001;96:2737-44.
16. Fontaine KR, Barofsky I. Obesity and health-related quality of life. Obes Rev 2001;2:173-82.
17. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatly liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-19.
18. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999;69:1108-16.
19. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
20. Chitturi S, Abeygunasekera S, Farrell G, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-9.
21. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
22. Ware JE jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
23. Australian Bureau of Statistics. National Health Survey: SF-36 Population Norms. Canberra, Australia: Australian Bureau of Statistics, 1995.
24. World Health Organisation. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: World Health Org, 1999 (available from http://whqlibdoc.who.int/hq/1999/ WHO_NCD_NCS_99.2.pdf, 1999).
25. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
26. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
27. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
28. Rothacker DQ, Blackburn GL. Obesity prevalence by age group and 5-year changes in adults residing in rural Wisconsin. J Am Diet Assoc 2000;100:784-90.
29. Schwartz M, Boyko E, Kahn S, et al. Reduced insulin secretion: an independent predictor of body weight gain. J Clin Endocrinol Metab 1995;80:1571-6.
30. Hoag S, Marshall JA, Jones RH, et al. High fasting insulin levels associated with lower rates of weight gain in persons with normal glucose tolerance: the San Luis Valley Diabetes Study. Int J Obes Relat Metab Disord 1995;19:175-80.
31. Perri MG, Nezu AM, Patti ET, et al. Effect of length of treatment on weight loss. J Consult Clin Psychol 1989;57:450-2.